Circulating tumor cells allow researchers to detect cancer early, provide an accurate prognosis, monitor progression, and ...

Recently, a review titled "Circulating tumor cell-derived organoids: current progress, applications, and future" was ...

Tumor-informed circulating tumor DNA (ctDNA) has shown promise as a biomarker for treatment response monitoring (TRM) in a variety of tumor types, with the potential to improve clinical outcomes. We ...

Large B-cell lymphomas (LBCL) are curable, but patients with residual disease after therapy invariably experience progression. Ultrasensitive methods to detect circulating tumor DNA (ctDNA) as minimal ...

A study led by scientists at NYU Langone Health and its Perlmutter Cancer Center has shown that monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer ...

In a pair of studies, investigators from the lab of Huiping Liu, MD, Ph.D., associate professor of Pharmacology and of ...

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) demonstrates that monitoring circulating tumor DNA (ctDNA) can refine ...

Circulating tumor DNA (ctDNA) is emerging as a promising biomarker to predict treatment response in patients with metastatic renal cell carcinoma (mRCC). In a recent study, Alan Tan, MD, of Vanderbilt ...

Signatera can detect tumor DNA in the bloodstream. A new blood test seeks to change the game in cancer management. Signatera, a "tumor-informed" blood test developed by Natera, can detect circulating ...

SECAUCUS, N.J., Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has ...